H20 Capital

H20 Capital is a Mexico City-based fund partnering with early-stage founders to build scalable digital marketplaces and health platforms. Check sizes of $250k to $1M place the firm in the seed range, suitable for participating in or anchoring small priced rounds. Healthcare exposure includes digital health and health IT. The firm is not specifically AI-focused, so AI-first founders should anchor their pitch in commercial outcomes rather than model architecture.

The firm’s natural fit is with Mexican and broader Hispanic-LatAm founders building technology platforms with marketplace dynamics, including healthcare-specific applications such as provider-patient marketplaces, telemedicine networks, pharmacy and diagnostic e-commerce, and care navigation platforms. The right founder profile is a Mexican-anchored team with credible local operational experience, building toward a regional or US-Hispanic expansion thesis. Founders building deep clinical assets, biotech, or pure US-market software without Latino orientation are not the natural target.

Geographically, H20’s advantage is the Mexican market itself, which is the second-largest economy in Latin America and the largest single market for many regional health-tech plays. The firm has connectivity to Mexican corporate stakeholders, regulatory bodies, and follow-on capital from larger LatAm and US funds. For founders looking to use Mexico City as a regional base, H20 is a credible early partner.

The right entry path is a warm intro from a portfolio founder or another regional VC. The firm reads partner-led decks and responds to clear marketplace theses with credible early traction. The pitch should lead with the marketplace dynamics (supply, demand, take rate, retention), unit economics in local currency, and a credible follow-on plan. Healthcare-specific pitches should address Mexican payer dynamics (IMSS, ISSSTE, private insurance, out-of-pocket) and regulatory considerations.

Caveats. Mexican fund structures interact with cross-border venture dynamics in idiosyncratic ways, including USMCA implications and US-Mexico tax considerations; engage regional counsel from day one. The firm’s healthcare-specific portfolio depth is not as visible publicly as its broader marketplace portfolio; reference calls with portfolio founders are advisable. The check size is moderate; for founders raising larger seeds, H20 should be a participant alongside a real lead. For Mexican-anchored health-tech founders building marketplaces with regional or US-Hispanic ambitions, H20 is a credible early partner; for founders without regional ties or marketplace dynamics, the fit is weaker.